Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia

International Journal of Clinical Pharmacy

Volumn 35, Issue 6, 2013, Pages 1099-1104

  Kuijvenhoven, Marianne A ^a   Haak, Eric A F ^b   Gombert Handoko, Kim B ^b   Crul, Mirjam ^b  

^a ZAANS MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

ACE inhibitors; Hyperkalemia; Potassium; Potassium influencing drugs; Potassium supplements; Potassium sparing diuretics; RAAS inhibitors; Renal function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; DIURETICS; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITALIZATION; HUMANS; HYPERKALEMIA; MALE; NETHERLANDS; POTASSIUM; PREVALENCE; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84892784481     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9830-8     Document Type: Article

References (14)

1. Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin N Am. 2005;23(3):723-47.
2. Paice B, Gray JMB, McBride D, Donnelly T, Lawson DH. Hyperkalemia in patients in hospital. BMJ. 1983;286:1189-92.
3. Acker GC, Johnson JJ, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8): 917-24.
4. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-9.
5. National Cancer Institute, U.S. department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010.
6. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351: 585-92.
7. Takaichi K, Takemoto F, Yoshifumi U, Mori Y. Analysis of factors causing hyperkalemia. Intern Med. 2007;46:823-9.
8. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351: 543-51.
9. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Lifethreatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-41.
10. Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Am J Med. 2009;122: 215-21.
11. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005;30:233-9.
12. Amir O, Hassan Y, Sarriff A, Awaisu A, Aziz NA, Ismail O. Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharm World Sci. 2009;31:287-93.
13. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AH, Grobbee DE, Moons KGM. Advantages of the nested case control design in diagnostic research. BMC Med Res Methodol. 2008;8:48.
14. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modification of diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):929-30.